Lv1
40 积分 2024-03-13 加入
Savolitinib in NSCLC: progress in the MET exon 14 journey
16小时前
待确认
Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective
1个月前
已关闭
Savolitinib in NSCLC: progress in the MET exon 14 journey
1个月前
已完结
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
1个月前
已完结
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
4个月前
已完结
Cost–effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung
4个月前
已完结
Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer
8个月前
已完结
中国阿尔兹海默病痴呆诊疗指南
9个月前
已完结
Interstitial Lung Disease
9个月前
已完结
皖公网安备34019202002308
